Memantine Hydrochloride Tablet
Product Images NDC 71335-1603

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1603). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure diagram of memantine hydrochloride showing its molecular framework with labeled functional groups NH2 and HCl, and methyl substitutions (CH3).*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph showing mean change from baseline in ADCS-ADL scores over weeks of treatment (0 to 28 weeks) comparing Placebo and Memantine Hydrochloride (M.HCl). The graph includes markers for average scores with error bars, illustrating clinical improvement and decline trends over time for each group.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage of patients line graph comparing the effects of Memantine Hydrochloride (M.HCl) and placebo on ADCS-ADL change from baseline. The x-axis represents change values, while the y-axis shows cumulative patient percentages. M.HCl is represented by circles, placebo by squares.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph showing mean (± SEM) change from baseline in SIB score over 28 weeks of treatment. The graph compares placebo and Memantine Hydrochloride (M.HCl) groups, with placebo showing a steady decline and M.HCl initially stable then a decline after week 16. The y-axis represents change in SIB score, with lines indicating clinical improvement and decline.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A line graph comparing cumulative percentage of patients versus SIB change from baseline for Memantine Hydrochloride (M. HCl) versus Placebo. The graph shows two lines: one for M. HCl with higher cumulative percentages over a range of SIB changes and one for Placebo with generally lower values.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph depicting the mean change with SEM from baseline in ADCS-ADL scores over 24 weeks of treatment comparing Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The x-axis shows Weeks of Treatment from 0 to 24, and the y-axis shows mean changes with a dotted line marking Clinical Improvement above zero and Clinical Decline below zero. Memantine groups show less decline than placebo over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A cumulative percentage graph showing the proportion of patients on the y-axis and the ADCS-ADL change from baseline on the x-axis. It compares treatment effects of Memantine Hydrochloride (M. HCl)/Donepezil versus Placebo/Donepezil, with data points represented by circles and squares respectively.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph showing the mean change from baseline in SIB Score over 24 weeks of treatment. The x-axis represents weeks of treatment, and the y-axis shows mean change with error bars. Two treatment groups are compared: Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The graph indicates trends in clinical improvement and decline across the treatment period.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

This chart displays a cumulative percentage of patients on the y-axis and SIB (Severe Impairment Battery) change from baseline on the x-axis. It compares two groups: Placebo/Donepezil (represented by square markers) and Memantine Hydrochloride/Donepezil (represented by circle markers), showing differences in patient response over a range of SIB changes.*

FDA Label Image

Label Image (Lbl713351603)

Label for Memantine HCl 10 mg tablet, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares the product to Namenda 10 mg tablet by Cadila Healthcare Limited and specifies a package quantity of 30 tablets. Storage instructions advise room temperature of 20°-25°C (68°-77°F) and to keep drugs out of reach of children. The NDC is 71335-1603-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.